Back to results
US 2015/0316556 A1Published application
Ssea4 and st3gal2 as chemotherapeutic drug response biomarkers
AssigneesMiltenyi Biotech GmbH, Xen Tech
InventorsOlaf Hardt, Andreas Bosio, Andrea Aloia, Jean-Gabriel Judde, Evgeniya Petrova, Stefano Cairo, Olivier Deas
Life of this patent
Estimating the term…
Abstract
The present invention provides the use of the biomarkers SSEA4 and/or ST3GAL2 for assessing the outcome for chemotherapeutic treatment of a cancer in an individual and methods thereof.
Claims12
(canceled)
A method for assessing the prognosis associated to resistance to chemotherapy in an individual having a cancer, the method comprising the steps of
- a) providing a sample to be tested
- b) detecting expression of SSEA4 in the test sample
- wherein the expression of SSEA4 in the test sample is indicative of a poor prognosis.
A method for assessing the prognosis associated to resistance to chemotherapy in an individual having a cancer, the method comprising the steps of
- a) providing a sample to be tested
- b) detecting the expression or activity level of ST3GAL2 in said sample
- c) comparing the detected expression or activity level to a control level
- d) determining said prognosis based on the comparison of c)
- wherein the control level is a good prognosis control level and an increase of the expression or activity level compared to the control level is determined as poor prognosis.
2 more elements
Dependencies are inferred from the claim text.